Justine Yang Bruce
Affiliation: University of Wisconsin
- Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomographyJustine Yang Bruce
Department of Medicine, University of Wisconsin Carbone Cancer Center, 7105 Wisconsin Institute Medical Research, 1111 Highland Ave, Madison, WI, 53705, USA
Cancer Chemother Pharmacol 76:187-95. 2015..Rapid disease progression associated with increased tumor proliferation has been observed during withdrawal of anti-angiogenic therapy. We characterize the dynamics of withdrawal flare for axitinib...
- A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignanciesJustine Yang Bruce
Section of Hematology Oncology, University of Wisconsin Carbone Cancer Center, 1111 Highland Avenue, Rm 7105, Madison, WI, 53705, USA
Cancer Chemother Pharmacol 73:485-93. 2014..We evaluated a sequential design administering bevacizumab during the sunitinib treatment break to suppress the sunitinib withdrawal flare...
- A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malateJustine Yang Bruce
Section of Hematology Oncology, University of Wisconsin Carbone Cancer Center, Wisconsin Institutes for Medical Research, Room 7105, 1111 Highland Avenue, Madison, WI 53705, USA
Invest New Drugs 30:794-802. 2012....
- Current controversies in the management of biochemical failure in prostate cancerJustine Yang Bruce
Division of Hematology Oncology, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin 53705 2275, USA
Clin Adv Hematol Oncol 10:716-22. 2012..Other management approaches under investigation include intermittent ADT, the combination of ADT and novel agents, and peripheral androgen blockade...